GSGTF - GenSight Biologics S.A.
| Previous close | 0.8000 |
| Open | 0.8000 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.8000 - 0.8000 |
| 52-week range | 0.8000 - 4.7500 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 36.947M |
| Beta (5Y monthly) | 2.09 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7300 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireGenSight Biologics Announces the Filing of its 2022 Universal Registration Document and Reschedules its Annual General Meeting on June 21, 2023
PARIS, May 10, 2023--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2022 Universal Registration Document (URD) in English with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference D.23-0406.
Business WireGenSight Biologics Announces the Re-approval of its Full Year 2022 Consolidated Financial Statements
PARIS, May 01, 2023--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announces that on April 28, 2023, the Board of Directors re-approved its full year 2022 consolidated financial statements, as updated to reflect the Company's recent decision to withdraw its European Medicines Agenc
Business WireGenSight Biologics Reports Cash Position as of March 31, 2023, and Provides Business Update
PARIS, April 20, 2023--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2023, and provided a business update.
Business WireGenSight Biologics Withdraws its EMA Application for LUMEVOQ®
PARIS, April 20, 2023--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announces that the Committee for Advanced Therapies (CAT)1 of the Committee Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) assessed the data presented during the oral
Business WireGenSight Biologics to Host a Webcast on April 5, 2023, to Provide an Update on LUMEVOQ® Manufacturing Following Investigations Findings
PARIS, April 04, 2023--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announces that its management team will host a live webcast on Wednesday, April 5, 2023, to provide update on LUMEVOQ® manufacturing issues encountered in March, following investigations findings at
Business WireGenSight Biologics Reports Full Year 2022 Consolidated Financial Results
PARIS, March 24, 2023--Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its full year 2022 consolidated financial results, as approved by the Board of Directors on March 23, 2023. Audit procedures on the Company’s 2022 consolidated financial statements were comp
Business WireGenSight Biologics Announces Presentation of LUMEVOQ® Efficacy and Safety Data from Early Access Programs for ND4-LHON Patients at NANOS 2023
PARIS, March 15, 2023--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314006021/en/
Business WireGenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 3-Year Follow-Up of REFLECT Phase III Trial
PARIS, March 13, 2023--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230312005028/en/
Business WireGenSight Biologics to Present at Upcoming Medical Conferences
PARIS, March 10, 2023--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the Company will participate and present LUMEVOQ® data at the following upcoming medical conferences taking place in the first half of 2023:
Business WireGenSight Biologics Announces Publication of LUMEVOQ® Safety Data over 5-Year Period in renowned Peer-Reviewed American Journal of Ophthalmology
PARIS, March 09, 2023--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the publication of a peer-reviewed article in the renowned American Journal of Ophthalmology focusing on pooled safety data from the 5 clinical studies with lenadogene nolparvovec (LUMEVOQ®). This analys
Business WireGenSight Biologics Provides Update on LUMEVOQ® Manufacturing and Commercialization Timelines
PARIS, March 07, 2023--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today provides an update on the manufacturing and commercialization timelines of LUMEVOQ®, the Company's gene therapy for Leber Hereditary Optic Neuropathy (LHON).
Business WireGenSight Biologics Announces its 2023 Financial Calendar
PARIS, February 28, 2023--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2023.
Business WireRare Disease Day 2023: GenSight Biologics Raises Awareness of Leber Hereditary Optic Neuropathy (LHON)
PARIS, February 28, 2023--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, highlights its commitment to fight rare neurodegenerative diseases by raising awareness of Leber Hereditary Optic Neuropathy (LHON) at Rare Disease Day through the launch of a European awareness campaign in Q1 2023,
Business WireGenSight Biologics Announces 1 Year Safety Data and Efficacy Signals from PIONEER Phase I/II Clinical Trial of GS030, an Optogenetic Treatment Candidate for Retinitis Pigmentosa
PARIS, February 13, 2023--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced favorable safety data and encouraging efficacy signals at 1 year post-gene therapy administration for the PIONEER Phase I/II clinical trial evaluating GS030 for the treatment of retinitis pigmentosa (
Business WireGenSight Biologics Announces the Drawdown of the First EUR 8 Million Tranche Under Its Credit Agreement With the European Investment Bank
PARIS, February 06, 2023--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the "Company"), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced today that it has received the payment of EUR 8 million under the first tranche (the "Tranche A") of the unsecured credit facility executed with the European Investment Bank (the "EIB") on N
Business WireGenSight Biologics Reports Cash Position as of December 31, 2022, FY 2022 Revenues and Provides Business Update
PARIS, January 26, 2023--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of December 31, 2022, revenues for the full year 2022 and provided a business update.
Business WireGenSight Biologics to Present at Upcoming Investor Conferences
PARIS, January 04, 2023--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the Company will participate in the following investor conferences in January 2023:
Business WireGenSight Biologics Secures €12 Million Financing Through a Premium Convertible Notes Issuance to an Institutional Investor and Provides Business Update
PARIS, December 23, 2022--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has signed a subscription agreement for a €12 million convertible notes financing from Heights Capital.
Business WireGenSight Biologics Announces Publication of Indirect Comparison of LUMEVOQ® Versus Natural History in ND4-LHON Patients in Peer-Reviewed Journal Ophthalmology and Therapy
PARIS, December 15, 2022--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214006010/en/
Business WireGenSight Biologics Announces Publication of Results of LUMEVOQ® REFLECT Pivotal Clinical Trial in Peer-Reviewed Journals
PARIS, November 17, 2022--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221116005984/en/
Business WireGenSight Biologics Secures a €35 Million Credit Facility From the European Investment Bank to Support the Launch of LUMEVOQ® in Europe
PARIS, November 04, 2022--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the "Company"), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has entered into a €35 million credit facility agreement with the European Investment Bank ("EIB"), supported by the European Fund for Strategic Investment (EFSI).
Business WireGenSight Biologics Reports Cash Position and Revenues as of September 30, 2022
PARIS, October 28, 2022--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position and revenues as of September 30, 2022.
Business WireGenSight Biologics to Present at Upcoming 2022 Medical Conferences
PARIS, September 29, 2022--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the Company will participate and present at the following upcoming medical conferences before the end of 2022:
Business WireGenSight Biologics to Present at Upcoming Industry and Investor Conferences
PARIS, September 20, 2022--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the Company will participate in the following industry and investor conferences:
Business WireGenSight Biologics Announces Successful Completion of LUMEVOQ® Engineering Batch Validating Implemented Corrective Actions
PARIS, September 19, 2022--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the successful completion of the first engineering batch incorporating refinements in the manufacturing process of LUMEVOQ®, the Company's gene therapy for Leber Hereditary Optic Neuropathy (LHON). T